Search results
Shining a light on World Sickle Cell Awareness Day. Learn more about this rare blood disorder
Delaware Online | The News Journal via Yahoo News· 1 day agoPeople living with sickle cell disease may experience intense pain and are highly susceptible to...
Roflumilast cream shows promise for long-term AD control By Investing.com
Investing.com· 2 days ago(NASDAQ:ARQT), a commercial-stage biopharmaceutical company, announced new study results today for...
Contraceptive Gel Shows Promise as New Form of Male Birth Control
Healthline via AOL· 5 days agoExperts are hopeful that this treatment, should it come to fruition in the long term, will provide...
Moderna's COVID-Flu Vaccine Shows Stronger Immune Response Than Individual Shots, Late-Stage Trial...
Forbes· 2 days agoModerna on Monday said its combination COVID-19 and flu shot elicits a stronger immune response...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoInvestigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment66.2% of participants treated ...
HMH Breaks Ground On Carrier Clinic Expansion Project
New Jersey Business Magazine· 2 days agoThe enhancement will allow Carrier Clinic, long a leader in the treatment of adolescents with...
Experts Focus on Quality-of-Life Data in Prostate Cancer
Medscape· 1 day agoSeveral trials presented at ASCO 2024 explored strategies to improve quality of life in patients with prostate cancer.
Male Birth Control: New Gel May Be Effective form of Contraceptive
Healthline· 5 days agoThe product, a gel, has shown effectiveness beyond what researchers initially expected. Experts are...
Veklury dosage: Forms, strengths, how to use, and more
Medical News Today· 6 days agoThe dosage can vary depending on how severe your condition is. Veklury is approved by the Food and...
...England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved...
Morningstar· 6 days agoGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA - Phase 2b Data ...